| Oct 8 |
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
|
| Oct 1 |
Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial
|
| Sep 19 |
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
|
| Sep 19 |
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
|
| Aug 14 |
Kiromic stock soars 65% on FDA fast track status for Deltacel
|
| Aug 14 |
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
|
| Aug 12 |
Kiromic reports update from Phase I NSCLC treatment trial
|
| Aug 9 |
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
|
| Aug 1 |
Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01
|
| Jul 18 |
Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
|
